Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
… As Roche Cuts In Diagnostics
by Ann M. Thayer
April 29, 2013
| A version of this story appeared in
Volume 91, Issue 17
Bowing to pricing pressures and funding cuts in life sciences research, Roche Diagnostics is dissolving its applied science unit. The move will cut about 110 jobs in Penzberg, Germany, and 60 in Branford, Conn. In 2012, the applied science unit had sales of about $808 million, or 7% of Roche Diagnostics’ total. The company will integrate the unit’s sequencing instruments into its other diagnostics businesses. Roche is also returning a semiconductor-based sequencing project to England’s DNA Electronics and has ended its partnership in nanopore-based sequencing with IBM.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter